Paranyline was used in dispersible formulations of anti-inflammatory agents. Information about the current use of this drug is not available.

FLUCIPRAZINE is an antitussive, antiemetic, neuroleptic agent.

Cinfenoac is a chalcone derivative patented by a pharmaceutical company Biorex Laboratories from the UK. The compound is claimed for the treatment of inflammatory and allergic conditions, as well as for the treatment of the ulcerous condition of the gastrointestinal tract.

Cinepaxadil is cinnamoyl-piperazine derivative developed by Delalande SA for treatment cardiovascular system disorders. Cinepaxadil decrease dogs cardiac activity after i.v. administration.

Amiflamine is a selective and reversible inhibitor of monoamine oxidase (MAO) type A which exerts a preferential effect on serotonin (5-HT) catabolism. The (+)-enantiomer is the active stereoisomer. In a series of p-aminosubstituted phenethylamines, the ( + )-enantiomer of the compound amiflamine (4-dimethylamino-2-a-dimethylphenethylamine) was found to be a potent, selective, and reversible MAO type A inhibitor. Amiflamine (FLA 336(+] and its two metabolites, FLA 788(+) and FLA 668(+) were found to be competitive inhibitors of the activity of monoamine oxidase-A in homogenates of human hypothalamus and liver obtained at autopsy. Ki values, determined at pH 7.2, were 1.3, 0.3 and 22 uM (liver) and 0.8, 0.2 and 14 uM (hypothalamus) for amiflamine, FLA 788(+) and FLA 668(+), respectively. Monoamine oxidase-B activity was only weakly inhibited by the compounds. This initial phase I study in six normal subjects showed that the new MAO inhibitor amiflamine can be tolerated in single oral doses up to 80 mg without significant pharmacologic effects. Doses up to 60 mg were tolerated without any subjective or objective effects.

Nitralamine is an antifungal agent.

Octasine is an antihistamine agent that has never been marketed.

Tonazocine is a nonpeptide, partial delta-opioid agonist with mu antagonist properties and weak k agonist activity. Tonazocine augmented the efficacy of L-DOPA in the reserpine model. Tonazocine evoked a dose-related, ipsilateral rotation, consistent with augmentation of dopaminergic function on the unlesioned side. Tonazocine has a narcotic antagonist activity which is 90 times that of pentazocine and 5 times less than that of naloxone as measured by the antagonism of morphine analgesia in the rat tail-flick test. Total pain relief scores for tonazocine 4 mg were nearly identical with that of morphine sulfate 10 mg while 8 mg of tonazocine were superior to 10 mg of morphine. Drowsiness was the main adverse reaction of tonazocine. Tonazocine has undergone phase II clinical trials for postoperative pain and appeared to possess reasonable efficacy.

In the early stages of testing was shown that it is about 4 times more potent than gallopamil and 12 times more potent than verapamil in its effects on smooth muscle tone and labeled calcium uptake.

Dipiproverine is the spasmolytic agent. It was used as anticholinergic drug.